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Abstract
Background and Aims: Little evidence exists from general population studies examining the association of non-alcoholic fatty liver disease (NAFLD) with 
cardiac structure and function, independent of adiposity. 
Methods: Cross-sectional study of a general population of adolescents (mean age 17 years). We estimated associations of 1. Blood-based markers of 
NAFLD: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) (N = 1,440) 2. Ultrasound (USS) diagnosed 
NAFLD and shear velocity (N = 654) with echocardiography-based measures of cardiac structure and function.
Results: ALT, AST, GGT and shear velocity were positively associated with left ventricular mass index [LVMI (g/m2.7)], mean difference (95% confidence 
intervals(CI)) per 10U/L for blood-based markers and per m/sec for shear velocity: 0.56 (0.28, 0.83), 0.40 (0.02, 0.77), 0.59 (0.36, 0.81) and 0.61 (0.13, 
1.09) when adjusting for age, sex, social class, pubertal status, smoking, and alcohol intake and with left a trial size index: 1.39% (0.66%, 2.13%), 1.28 (0.30, 
2.28), 1.01 (0.43, 1.59) and 2.56 (1.21, 3.93) respectively. After additional adjustment for fat mass, only GGT remained associated with LVMI: 0.29 (0.09, 
0.50). GGT and shear velocity were inversely associated with peak myocardial wall velocity in systole in confounder-adjusted models including fat mass. ALT, 
AST and GGT were positively associated with left ventricular diastolic diameter in age and sex-adjusted model, but associations attenuated in confounder-
adjusted models. No associations between measures of NAFLD and relative wall thickness, mid wall fractional shortening, ejection fraction, E/e’, mitral E/A, 
and e’ were found and there was no difference in any measures of cardiac structure and function between adolescents with (N = 13) and without USS fatty 
liver (N = 641).
Conclusions: We found no robust evidence that markers of NAFLD are associated with cardiac structure or function independent of adiposity in a general 
adolescent population.
ABBREVIATIONSLVMI: Left Ventricular Mass Indexed to height2.7; RWT: Left Ventricular Relative Wall Thickness; LAI: Left Atrial Size Indexed to height2.7; E/e: Diastolic Transmitral flow velocity; E/A: Ratio of 
Early Late Transmitral Flow Velocity; e: Early Diastolic Velocity 
INTRODUCTION Cardiovascular disease (CVD) is the leading cause of 
mortality amongst adults with non-alcoholic fatty liver disease 
(NAFLD) [1,2]. NAFLD is associated with greater carotid intima 
media thickness [3], higher blood pressure [4-6], adverse 
cardiac structure and function [7-10], dyslipidemia [6] and 
hyperglycaemia [4], even after adjusting for established CVD 
risk factors including whole body adiposity and lipid levels. 
Consequently, it has been suggested that NAFLD is implicated 
in the development of CVD through systematic processes such 
as insulin resistance, low-grade inflammation, and myocardial 
lipid accumulation due to increased free fatty acid flux [11,12]. 
However, other reports suggest that the association between 
NAFLD and cardiac structure and function is not independent but 
driven by a common cause - adiposity [13,14].
Measures of cardiac structure, diastolic and systolic function in 
childhood track through to adulthood [15,16] and are predictors 
of CVD later in life [17]. Adiposity is closely associated with both 
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NAFLD [18] and altered cardiac function [19-21] and therefore it 
is plausible that associations between the latter are confounded 
by adiposity. The majority of studies that have reported adverse 
cardiac structure and function in adolescents with NAFLD have 
been conducted in selected obese populations [22,23] and there 
is a paucity of evidence from the general adolescent population.
We examined associations of markers of NAFLD: Alanine 
Amino Transferase (ALT), aspartate amino transferase (AST) and 
gamma-glutamyltransferase (GGT) and ultrasound scan (USS) 
assessed fatty liver and shear velocity (a marker of liver fibrosis/
stiffness), with measures of cardiac structure and function in 
a general population sample of adolescents. We also aimed to 
examine whether any associations found were confounded by 
adiposity.
METHODS 
Study participants
The Avon Longitudinal Study of Parents and Children 
(ALSPAC) is a prospective, population-based birth cohort study 
that recruited 14,541 pregnancies, of which there were 13,867 
live births from 13,761 women in Avon, UK, with expected dates 
of delivery 1st April 1991 to 31st December 1992 (http://www.
alspac.bris.ac.uk) [24,25]. Please note that the study website 
contains details of all the data that is available through a fully 
searchable data dictionary. 
The cohort has been followed-up since birth with 
questionnaires, and from the age of seven participants has been 
seen regularly in clinic; the most recent of these was the 17-18 
year clinic assessment. This clinic assessment was attended by 
5,206 participants, and included two separate sub-studies. In 
one, liver ultrasounds (USS) were conducted and in the other, 
echocardiography measures were taken. To be eligible for the 
present study, participants had to have blood-based markers of 
NAFLD and/or participated in the echocardiography sub-study. 
Singletons and one randomly chosen twin from twin pairs was 
included (see Figure 1). 
In order to remove any effect due to excess alcohol intake, 
which is associated with fatty infiltration in the liver, consistent 
harmful alcohol drinkers were removed from the analysis. 
Information on participant’s alcohol consumption was obtained 
by questionnaires administered at age 16 years, and again at 17 
years (at the same time as the USS assessment), using the Alcohol 
Use Disorders Identification Tests (AUDIT) questionnaire 
[26]. Participants answered 10 questions about their alcohol 
consumption, and from their responses, a score between 0 and 
20 was derived. A score over 16 is classified as harmful alcohol 
consumption [26]. Consistent harmful alcohol drinkers were 
defined by a score of 16 or greater at both 16 years and 17 years. 
No participants had a known history of jaundice or hepatitis, 
or were taking medications or receiving treatment that would 
Figure 1 Participants’ flow diagram through the study and the numbers included in each of the main analyses.
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indicate they had hepatic disease, or were known to influence liver function.
Ethical approval for this study was obtained from the ALSPAC 
Law and Ethics Committee and the Local National Health Service 
Research Ethics Committee. All participants provided written informed consent. 
Blood-based outcomes and liver ultrasound scans
For both the blood-based analyses and liver USS participants 
were fasted overnight, for those attending clinic in the morning, 
or for a minimum of 6 hours, for those attending clinic after lunch. 
Assessment of blood-based measures
Fasting blood samples were immediately spun and frozen at 
-80°C. Measurements were assayed shortly (3-9 months) after 
samples were taken with no previous freeze-thaw cycles. All 
assays were completed in the same laboratory at the University 
of Glasgow. ALT, AST and GGT were measured by an automated 
analyser with enzymatic methods.
Liver ultrasound scans
A detailed description of the liver ultrasound scans has been 
published previously [27]. Briefly, upper abdominal USS was 
completed by one of four trained sonographers using a Siemens 
Acuson S2000 USS system, with the participant at rest in the 
dorsal decubitus position. Echogenicity (our marker of liver fat) 
was assessed during deep inspiration and recorded as present, 
absent or uncertain according to established protocols using the 
right kidney as the reference organ [28]. All participants were 
classified as having absent or present echogenicity; no ‘uncertain’ 
echogenicity was noted. 
Acoustic radiation force impulse-imaging (ARFI) of the right 
lobe of the liver was used to measure liver stiffness (or fibrosis), 
using standard protocols [29,30]. ARFI (measured as shear 
velocity in meters/second [m/s]) was assessed six times with a 
gap of at least 1 minute between each measurement. The highest 
and lowest of these measurements were excluded and the 
Siemens Acuson S2000 system produced a mean of the remaining 
four measurements. In the analyses we have used the mean of 
four measurements after the highest and lowest velocities (of the 
six taken) were removed. When both right and left lobe values 
were available the lowest mean of the two has been used. 
Assessment of cardiac structure and function
Echocardiography was performed using a HDI 5000 
ultrasound machine (Phillips) equipped with a P4-2 Phased 
Array ultrasound transducer by one of two echo cardiographers 
using a standard examination protocol. All measurements were 
made according to American Society of Echocardiography 
(ASE) guidelines [31] and left ventricular mass and relative wall 
thickness (RWT) were calculated using validated equations. To 
account for differences in body size, left ventricular mass and 
left atrial size (anteroposterior dimension) were indexed to height2.7 (LVMI2.7 and LAI2.7) [32]. Pulsed Doppler examination 
of transmitral flow was recorded from the apical four chamber 
view. For left ventricular measurements the sample volume 
was positioned between the mitral annulus and the tips of the 
mitral leaflets with the position adjusted to maintain the sample 
volume at an angle as near parallel to transmitral flow as possible 
with the participant in passive end expiration. The peak flow 
velocities of the early (E) and atrial (A) transmitral inflow pattern 
were measured from three cardiac cycles displaying the highest 
measurable velocity profiles. The ratio of the early and atrial 
peak flow velocities (E/A) were calculated as a measure of left 
ventricular diastolic function. Similar measurements were also 
made at the tricuspid valve. Tissue Doppler echocardiography 
(TDE) was performed in the 4 chamber view on the lateral left 
ventricular wall to obtain peak myocardial wall velocities in 
systole (s′) and early and late diastole (e′ and a′ respectively). 
Data were acquired with the beam parallel to the wall of interest 
and with settings optimized to ensure no over-gain of the low 
velocity signals. A 5 mm sample volume was placed at the level 
of the mitral valve annulus and still images of 8-10 cardiac 
cycles were recorded. On-going quality control was performed 
throughout the study and reproducibility of echocardiographic 
measurement was assessed by recalling 30 participants and 
repeating their measurements. The intra-class correlation of 
repeated echocardiographic measurements was excellent: 0.75 
to 0.93 (intra-observer) and 0.78 to 0.93 (inter-observer). 
Assessment of other variables
Parental occupation was used to derive household 
occupational social class, with each household assigned 
the highest parental occupational (classes I (professional / 
managerial) to V (unskilled manual workers), using the 1991 
British Office of Population and Census Statistics (OPCS) 
classification). The participant’s age was calculated in months 
from their date of birth and date of attendance at the clinic 
assessment. Height was measured without shoes to the nearest 
0.1cm using a Harpenden stadiometer. A Lunar Prodigy narrow 
fan beam densitometer was used to perform a whole body dual-
energy X-ray absorptiometry (DXA) scan from which lean and 
fat mass were measured. Puberty information was collected 
at age 17 by postal questionnaire based on the Tanner staging 
system. Pubertal stage was based on pubic hair staging for male 
participants and pubic hair and breast staging for females. If both 
were available then the higher grade was used. Data on daily 
cigarette smoking was collected via postal questionnaire at age 
16.5 years. 
Statistical analysis
All analyses were conducted using Stata version 13.0 MP2 
(Stata Inc., TX, USA). Outcome variables of cardiac structure and 
function that were right skewed were log transformed so that 
residuals in models would be approximately normal. For these 
outcomes we back-transformed the coefficients and present them 
as a % mean difference per unit exposure. A series of multivariable 
regression models were constructed in order to examine the 
associations between continuous measures of liver pathology 
(ALT, GGT, AST and USS assessed liver stiffness) and cardiac 
structure and function and to explore the impact of adjustment 
for potential confounding factors. In the basic model we 
controlled for age and sex (model 1). In the confounder adjusted 
model we additionally adjusted for household social class, 
pubertal stage, smoking and alcohol intake and DXA-assessed fat 
Central
Bringing Excellence in Open Access


Fraser et al. (2016)
Email: 
J Endocrinol Diabetes Obes 4(3): 1091 (2016) 4/10
mass (and height and height-squared to remove any association 
of fat mass with height) (model 2). Results are presented as mean 
differences; for naturally logged outcome variables, coefficients 
were back transformed and multiplied by 100 to give a difference 
in means presented as a percentage. In sensitivity analyses, we 
examined whether adjustment for BMI instead of DXA-assessed 
fat mass altered results (model 2). Age and sex adjusted outcome 
measures were compared for participants with USS diagnosed 
fatty liver fat (N = 13) and without.
Dealing with missing data and additional analyses
Of the eligible participants (those included in the liver 
ultrasound study and/or blood-based markers available, not 
classed as consistent harmful drinkers, with at least one measure 
from the echocardiography), a proportion had missing data on 
any of exposures, outcomes and potential confounding factors 
(extent of missing for any single variable included in analyses 
varied from 0-37.4% (Table S1,S2). To increase efficiency and 
minimise selection bias we used multivariate multiple imputation 
to impute missing data for any of the eligible participants with 
missing data. We included all exposures, co variables, outcomes 
and potential predictors of missing data in the imputation. We 
generated 40 imputed datasets that were combined by Rubin’s 
rules [33]. 
RESULTS 
Table 1 shows the characteristics of participants who were 
included in either the blood-based outcome analyses and/ or USS 
based outcomes. The prevalence of USS fatty liver was 2.2% (N 
= 13). The distribution of characteristics in the observed dataset 
was similar to those in the imputed datasets (Supplementary 
web Table S1,S2). 
Table 2 shows the multivariable associations of blood-based 
markers of NAFLD and shear velocity (a measure of liver stiffness) 
with measures of cardiac structure and function. Higher ALT, 
AST, GGT and shear velocity were associated with higher LVMI 
in model 1, but, with the exception of GGT, these associations 
attenuated to the null in the confounder adjusted model (model 
2). This attenuation, which also affected the association of GGT, 
was largely due to adjustment for fat mass. 
There was weak evidence of a positive association of shear 
velocity with relative wall thickness (RWT) in both models but 
no strong evidence of associations of ALT, AST or GGT with RWT 
(Table 2). GGT and shear velocity were inversely associated 
with s’ in both models. There was no evidence of associations of 
ALT and AST with s’, or for any of the exposures with mid wall 
fractional shortening and ejection fraction. 
ALT, AST, GGT and sheer velocity were positively associated 
with LAI (indexed to height2.7) in model 1, but again attenuated 
in the confounder adjusted model, largely due to adjustment for fat mass. 
Weak evidence of positive associations between GGT and E/e’ 
and of shear velocity with mitral E/A emerged only in model 2, 
i.e. with adjustment for confounders. ALT, AST and GGT were 
positively associated with left ventricular diastolic diameter in 
model 1, but attenuated to the null in the confounder adjusted 
model, largely due to the confounding effect of fat mass. No 
associations between liver markers and e’ were observed. 
There were no notable differences in the associations of 
markers of NAFLD with measures of cardiac structure and 
function when BMI (instead of fat mass) was used as a measure 
of adiposity(data not shown but available on request). We 
also examined (post hoc) whether height was a confounder in 
associations between measures of liver health and LVMI and LAI, 
but when height (but not fat mass or BMI) was accounted for, 
associations remained essentially unaltered. 
There was no evidence of a difference in any measures of 
cardiac structure and function between adolescents with (N = 
13) and without USS fatty liver (N = 641) (Table 3). 
DISCUSSION 
We conducted a detailed analysis of the associations of 
several markers of NAFLD with a range of measures of cardiac 
structure and function assessed at the same time. Of 50 tested 
associations, there was statistical evidence to support only three 
(6%) after adjustment for confounders (i.e. very similar to what 
we would expect by chance with a 5% significance level). Fat 
mass (or alternatively BMI) was the most important confounder, 
resulting in marked attenuation of any age and sex adjusted 
estimate. Taken together these findings suggest that NAFLD is not 
an independent (of adiposity) determinant of cardiac structure or function in adolescence.
Of the three associations that were observed in confounder 
adjusted models, it is possible that associations of GGT (but not of 
ALT and AST) with LVMI and s’ reflect extra hepatic sources of GGT 
consistent with its possible role as a biomarker of cardiovascular 
disease [34]. Associations between shear velocity and s’ may be 
due to shear velocity being a measure of liver stiffness and thus 
reflecting more severe NAFLD. However, GGT and shear velocity 
were not consistently associated with other measures of cardiac structure and function and given that these three associations are 
6% of the 50 tested, and we would expect 5% by chance alone, we 
should assume that these are chance findings unless replicated in other studies. 
Obesity is closely related to adverse cardiac structure and 
function changes even in adolescents and young adults [35]. 
Studies in children and adolescents have reported associations 
between obesity and cardiac remodelling, including increased 
left atrial volume, left ventricular mass indexed to height and 
left ventricular diastolic volume [36]. In our population of 
adolescents, measures of NAFLD were largely not associated with 
cardiac structure and function independently of total fat mass or 
BMI.
Some cross-sectional studies in adult populations, but not all 
[18], have reported positive associations of NAFLD with cardiac 
measures, including left ventricular diastolic function [7,8] and 
left ventricular hypertrophy [9] even after adjusting for adiposity. 
It is possible that the discrepancy between results of studies in 
adults and our own is due to youth of the participants and/or the 
relatively short exposure time; perhaps exposure NAFLD has a cumulative effect over time and therefore its adverse effects on cardiac structure and function emerge later in life.
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Table 1: Characteristics of participants with available data on USS-based and blood-based measures of NAFLD.
Characteristic USS-based measures of NAFLD Blood-based measures of NAFLD
N Mean (SD) or median (IQR) or N (%) as indicated N
Mean (SD) or median (IQR) or N (%) 
as indicated
Male (%, N) 654 268 (41.0) 1,440 710 (49.3)
Age, months (mean, SD) 654 213.7 (4.5) 1,440 212.3 (4.0)
Manual social class, (%, N) 566 87 (15.4) 1,279 161 (12.6)
Post puberty, (%, N) 409 353 (86.3) 955 810 (84.8)
Smoker, (%, N) 463 41 (8.9) 1,060 96 (9.1)
Alcohol intake (AUDIT score), (%, N)
0-7
8-15
16+
617
404 (65.5)
189 (30.6)
24 (3.9)
1,380
867 (62.8)
456 (33.0)
57 (4.1)
BMI, kg/m2 (median, IQR) 654 22.4 (20.3, 25.2) 1,440 22.0 (20.1, 24.7)
Fat mass, kg 
(median, IQR)
641 17.4 (119, 24.6) 1,407 16.1 (10.2, 23.2)
Height, cm (mean, SD) 636 170.4 (9.6) 1,414 171.9 (9.4)
ALT, U/l (median, IQR) 470 15.3 (12.0, 19.3) 1,440 14.7 (11.7, 19.2)
AST, U/l (median, IQR) 470 19.3 (16.8, 22.8) 1,440 19.4 (16.6, 23.1)
GGT, U/l (median, IQR) 469 16.0 (13.0, 20.0) 1,439 16.0 (13.0, 21.0)
Ultrasound fatty liver, (%, N) 593 13 (2.2) n/a
Ultrasound shear velocity, m/sec 
(median, IQR)
598 1.2 (1.1, 1.3) n/aLeft ventricular mass indexed to height2.7, g/m2.7(mean, SD) 633 28.3 (5.9) 1,403 29.1 (6.2)
Relative wall thickness (mean, SD) 650 0.4 (0.05) 1,429 0.4 (0.1)
Average lateral wave, s’, cm/s 
(median, IQR)
634 8.5 (7.4, 9.8) 1,405 8.4 (7.3, 9.8)
Midwall fractional shortening, % 
(mean, SD)
650 15.9 (2.2) 1,429 15.5 (2.2)
Ejection fraction, %, (mean, SD) 651 66.5 (6.4) 1,430 66.3 (6.5)
Lateral E/e’ ratio (median, IQR) 630 4.8 (4.2, 5.3) 1,389 4.8 (4.2, 5.4)
Mitral E/A (median, IQR) 634 1.9 (1.6, 2.1) 1,399 1.9 (1.6, 2.1)
Left atrial size indexed to height, 
cm/m(median, IQR)
584 0.8 (0.7, 0.9) 1,273 0.7 (0.7, 0.8)
eʼ, cm/s (median, IQR) 634 13.3 (11.7, 15.0) 1,405 13.1 (11.5, 14.9)
Left ventricular diastolic diameter, 
cm (mean, SD)
651 4.5 (4.2, 4.8)
1,430
4.5 (0.4)
a: P-value for the null hypothesis of no difference compared to those included in either analysis of blood based or USS outcomes group (reference 
group)
Abbreviations: USS: Ultrasound Scan; ALT: Alanine Amino Transferase; AST: Aspartate Amino Transferase; GGT: Gamma-Glutamyl Transferase; 
IQR:  Interquartile Range; SD: Standard Deviation; N/A: Not Applicable
Table 2: Multivariable associations of shear velocity (N=654) and blood-based markers (N=1,440) of non-alcoholic fatty liver disease with measures of cardiac structure and function.
Model 1 Model 2 
Mean differences or % mean 
differences (95% CI) P value 
Mean differences or % mean 
differences (95% CI) P value 
Ventricular structure
Left ventricular mass indexed to height2.7 (g/m2.7)
ALT per 10 U/l 0.57 (0.29, 0.85) <0.001 0.11 (-0.25, 0.27) 0.94
AST per 10 U/l 0.39 (0.02, 0.76) 0.04 0.12 (-0.22, 0.46) 0.48
GGT per 10 U/l 0.59 (0.37, 0.81) <0.001 0.29 (0.09, 0.50) 0.005
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Table 2: Multivariable associations of shear velocity (N=654) and blood-based markers (N=1,440) of non-alcoholic fatty liver disease with measures of cardiac structure and function.
Model 1 Model 2 
Mean differences or % mean 
differences (95% CI) P value 
Mean differences or % mean 
differences (95% CI) P value 
Shear velocity per SD (m/sec) 0.67 (0.20, 1.15) 0.006 0.01 (-0.43, 0.44) 0.98
Relative wall thickness
ALT per 10 U/l -0.0001 (-0.0028, 0.0026) 0.94 -0.0009 (-0.0037, 0.0019) 0.52
AST per 10 U/l -0.0016 (-0.0051, 0.0020) 0.39 -0.0019 (-0.0054, 0.0017) 0.31
GGT per 10 U/l 0.0013 (-0.0008, 0.0034) 0.23 -0.0009 (-0.0013, 0.0030) 0.43
Shear velocity per SD (m/sec) 0.0036 (-0.0002, 0.0074) 0.07 0.0032 (-0.0008, 0.0072) 0.12
Systolic function
sʼ  (%a)
ALT per 10 U/l 0.18 (-0.77, 1.14) 0.71 0.41 (-0.56, 1.40) 0.41
AST per 10 U/l -0.39 (-1.67, 0.90) 0.55 -0.28 (-1.56, 1.02) 0.68
GGT per 10 U/l -0.91 (-1.64, -0.16) 0.02 -0.83 (-1.58, -0.08) 0.03
Shear velocity per SD (m/sec) -2.71 (-4.31, -1.08) 0.001 -2.45 (-4.11, -0.76) 0.005
Midwall fractional shortening (%)
ALT per 10 U/l -0.10 (-0.29, 0.09) 0.55 0.02 (-0.08, 0.12) 0.71
AST per 10 U/l 0.08 (-0.05, 0.21) 0.22 0.09 (-0.04, 0.23) 0.16
GGT per 10 U/l -0.05 (-0.13, 0.03) 0.21 -0.02 (-0.10, 0.06) 0.63
Shear velocity per SD (m/sec) -0.02 (-0.19, 0.16) 0.86 0.04 (-0.14, 0.22) 0.67
Ejection fraction (%)
ALT per 10 U/l 0.02 (-0.32, 0.27) 0.88 0.05 (-0.26, 0.35) 0.77
AST per 10 U/l 0.08 (-0.30, 0.47) 0.67 0.09 (-0.30, 0.48) 0.65
GGT per 10 U/l -0.03 (-0.27, 0.20) 0.77 0.01 (-0.22, 0.25) 0.92
Shear velocity per SD (m/sec) 0.18 (-0.34, 0.70) 0.50 0.28 (-0.26, 0.82) 0.31
Diastolic function
E/eʼ  (%a)
ALT per 10 U/l -0.22 (-1.14, 0.70) 0.64 0.26 (-0.69, 1.22) 0.59
AST per 10 U/l -0.24 (-1.51, 1.04) 0.71 -0.06 (-1.33, 1.23) 0.93
GGT per 10 U/l 0.40 (-0.33, 1.13) 0.29 0.70 (-0.04, 1.45) 0.07
Shear velocity per SD (m/sec) 0.68 (-0.93, 2.31) 0.41 1.01 (-0.65, 2.70) 0.23
Mitral E/A(%a)
ALT per 10 U/l -0.79 (-1.69, 0.11) 0.09 -0.16 (-1.08, 0.77) 0.74
AST per 10 U/l 0.14 (-1.08, 1.38) 0.82 0.40 (-0.82, 1.64) 0.52
GGT per 10 U/l -0.64 (-1.34, 0.07) 0.08 -0.29 (-1.00, 0.43) 0.43
Shear velocity per SD (m/sec) 0.75 (-0.85, 2.39) 0.36 1.56 (-0.10, 3.25) 0.07
Left atrial size indexed to height(%a)
ALT per 10 U/l 1.37 (0.64, 2.11) <0.001 0.25 (-0.32, 0.82) 0.40
AST per 10 U/l 1.28 (0.30, 2.28) 0.01 0.52 (-0.22, 1.27) 0.17
GGT per 10 U/l 0.97 (0.39, 1.55) 0.001 0.37 (-0.07, 0.81) 0.10
Shear velocity per SD (m/sec) 2.53 (1.18, 3.89) <0.001 1.13 (0.13, 2.13) 0.36
eʼ (%a)
ALT per 10 U/l 0.68 (-0.27, 1.63) 0.16 0.43 (-0.54, 1.42) 0.39
AST per 10 U/l 0.30 (-0.98, 1.59) 0.65 0.12 (-1.16, 1.42) 0.85
GGT per 10 U/l -0.23 (-0.97, 0.52) 0.54 -0.39 (-1.14, 0.37). 0.31
Shear velocity per SD (m/sec) 0.33 (-1.32, 2.00) 0.70 0.08 (-1.60, 1.80) 0.93
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Table 2: Multivariable associations of shear velocity (N=654) and blood-based markers (N=1,440) of non-alcoholic fatty liver disease with measures of cardiac structure and function.
Model 1 Model 2 
Mean differences or % mean 
differences (95% CI) P value 
Mean differences or % mean 
differences (95% CI) P value 
Left ventricular diastolic diameter (cm)
ALT per 10 U/l 0.02 (0.00, 0.04) 0.02 0.00 (-0.02, 0.02) 0.85
AST per 10 U/l 0.03 (0.00, 0.05) 0.03 0.02 (-0.00, 0.04) 0.07
GGT per 10 U/l 0.02 (0.01, 0.03) 0.01 0.01 (-0.01, 0.02) 0.25
Shear velocity per SD (m/sec) 0.02 (-0.01, 0.05) 0.22 -0.01 (-0.04, 0.02) 0.47
ALT: Alanine Amino Transferase; AST: Aspartate Amino Transferase; GGT: Gamma-Glutamyl Transferase
The null value for all analyses is 0. 
Model 1 (basic model): age at time of assessment and gender
Model 2 (confounder adjusted model): as model 1 plus social class and puberty, smoking, alcohol intake, fat mass, height and height squaredaFor these results the outcome was log-transformed and the regression coefficient back transformed so that the results are the % difference of 
outcome per unit of exposure.
Table 3: Age and gender adjusted values of cardiac structure and function measures by USS-determined fatty liver (N=654).
Mean or geometric means of cardiac structure and function 
measures (95% CI) by whether the participant had USS-
determined fatty liver 
P value
Yes (N=13) No (N=641)
Ventricular structureLeft ventricular mass indexed to height2.7, g/m2.7 30.4 (26.9, 34.0) 29.3 (27.9, 28.8) 0.42
Relative wall thickness 0.4 (0.4, 0.4) 0.4 (0.4, 0.4) 0.62
Systolic function
sʼ, cm/s 8.3 (7.5, 9.1) 8.5 (8.3, 8.6) 0.43
Midwall fractional shortening, % 15.5 (14.4, 16.5) 15.9 (15.7, 16.1) 0.69
Ejection fraction, % 65.9 (62.7, 69.0) 66.5 (66.0, 67.0) 0.96
Diastolic function
E/eʼ 5.0 (4.5, 4.8) 4.7 (4.7, 4.8) 0.21Mitral E/A 1.8 (1.7, 2.0) 1.9 (1.8, 1.9) 0.51
Left atrial size indexed to height, cm/m 0.8 (0.7, 0.8) 0.8 (0.7, 0.8) 0.40
eʼ, cm/s 13.0 (11.7, 14.4) 13.3 (13.1, 13.5) 0.66
Left ventricular end diastolic diameter, cm 4.7 (4.5, 4.9) 4.5 (4.5, 4.6) 0.78
CI: confidence intervals
To our knowledge this is the first study that has considered 
the association between NAFLD and cardiac structure and 
function in a general population sample of adolescents; other 
studies in adolescents have been mainly in selected obese 
populations [22,23,37-39]. Similar to our results the majority 
of these studies reported a crude positive association of NAFLD 
with LVMI [22,23,37,38] Singh et al., [39] compared 3 groups of 
adolescents; lean adolescents, obese adolescents without NAFLD 
and obese adolescents with NAFLD (determined by magnetic 
resonance spectroscopy). They found greater LVMI in obese (n 
= 30) compared to lean (n = 14) adolescents at a median age of 
15 years, but no strong evidence of a difference between obese 
participants with (n = 15) and without NAFLD (n = 15), possibly 
indicating that the association was driven by adiposity and not by 
the presence of NAFLD. 
Other studies in selected obese samples have reported 
associations between NAFLD and cardiac structure even after 
adjusting for adiposity and other CVD risk factors. Pacifico et al., 
[23] reported a greater E/eʼ ratio in obese NAFLD participants 
(N = 54) compared to obese non-NAFLD (N = 54) and lean 
participants (N = 18) in unadjusted analysis. In multivariable 
analysis, E/e’ was dichotomised (using the median value of 6.83) 
and after adjusting for age, sex, puberty, BMI, abdominal fat, 
systolic and diastolic blood pressure, triglycerides, HDLc, and 
whole-body insulin sensitivity index, NAFLD remained associated 
with high E/e’. In a study examining the association of NAFLD in 
obese adolescents mean age 13.5 years, (n = 97) with LVM, age, 
total cholesterol, AST and insulin sensitivity were associated with 
LVM in multivariable analysis [22]. The results from these two 
studies differ from our findings, which may reflect the differences 
in the study samples’ adiposity levels.
The work presented here extends earlier work conducted 
using data from the same sample of adolescent participants in 
the ALSPAC, which demonstrated that association of markers of 
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NAFLD, including USS-determined fatty liver with central and 
peripheral systolic blood pressure, diastolic blood pressure, and 
mean arterial pressure were confounded by adiposity [40], whilst 
associations of USS fatty liver with greater insulin resistance and 
dyslipidemia, persisted even after adjusting for measures of 
adiposity [27].
STRENGTHS AND LIMITATIONS
This study is the largest to date that has examined the 
association of several measures of liver health with cardiac 
structure and function in an unselected cohort of healthy 
adolescents. Whilst the proportion of participants with USS 
determined NAFLD in our cohort is lower than that observed in 
another study of healthy 11-13 year olds in Southern Italy [41] 
it is within the range of reported estimates [42,43]. The number 
of participants with NAFLD in our study is small (n = 13) and 
therefore the lack of associations seen for that exposure after 
adjustment may be due to lack of statistical power. 
Although USS-determined NAFLD is not the gold-standard, 
undertaking biopsies to determine NAFLD status in a large 
healthy population, as described in this study, would be unethical. 
In general, USS, has a sensitivity of 85-90% and specificity of 70-
85% for detecting liver fat of at least 10%, but lower sensitivity 
and specificity for lower levels of fat [44]. Therefore, it is likely 
that NAFLD in our cohort reflect the prevalence of the more 
moderate to severe end of the spectrum. Moreover, studies in 
children have shown USS to accurately identify moderate to 
severe steatosis compared with liver biopsy [45], The ARFI 
measure of liver stiffness used in our study is a relatively new 
measure, but has been validated in a small number of clinical 
studies [46,47]. Cardiac structure and function were assessed by 
ultrasound which does not detect sub-clinical changes in cardiac 
function, such as cardiac torsion. The majority of this population 
are of European origin and we cannot assume that results 
generalise to other populations. Finally, our study is cross-
sectional and further follow-up of this cohort will be valuable in 
determining whether associations change over time.
CONCLUSION
Our results suggests that in a general population of 
adolescents, markers of NAFLD are not associated with cardiac 
structure or function once the confounding effect of adiposity has 
been taken into account. These results support the importance of 
weight management in the preservation of cardiac function, but 
do not support specialist approaches targeting liver lipid content 
for optimising cardiac function in this population. 
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